These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 18626181

  • 21. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
    Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
    [Abstract] [Full Text] [Related]

  • 22. Acute myopericarditis following intravenous zoledronic acid for the treatment of Paget's disease.
    Watts MR, Ellims AH, Eccleston DS.
    Med J Aust; 2014 Feb 17; 200(3):150. PubMed ID: 24528425
    [No Abstract] [Full Text] [Related]

  • 23. Zoledronic acid and atrial fibrillation in cancer patients.
    Arslan C, Aksoy S, Dizdar O, Dede DS, Harputluoglu H, Altundag K.
    Support Care Cancer; 2011 Mar 17; 19(3):425-30. PubMed ID: 20358384
    [Abstract] [Full Text] [Related]

  • 24. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
    Pilanci KN, Alco G, Ordu C, Sarsenov D, Celebi F, Erdogan Z, Agacayak F, Ilgun S, Tecimer C, Demir G, Eralp Y, Okkan S, Ozmen V.
    Medicine (Baltimore); 2015 May 17; 94(18):e671. PubMed ID: 25950681
    [Abstract] [Full Text] [Related]

  • 25. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
    Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A.
    Support Care Cancer; 2016 Jan 17; 24(1):447-455. PubMed ID: 26335402
    [Abstract] [Full Text] [Related]

  • 26. Yearly zoledronic acid in postmenopausal osteoporosis.
    Poole KE, Kaptoge S, Reeve J.
    N Engl J Med; 2007 Aug 16; 357(7):711-2; author reply 714-5. PubMed ID: 17703530
    [No Abstract] [Full Text] [Related]

  • 27. Zoledronic acid: a review of its use in breast cancer.
    Lyseng-Williamson KA.
    Drugs; 2008 Aug 16; 68(18):2661-82. PubMed ID: 19093706
    [Abstract] [Full Text] [Related]

  • 28. Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer.
    Moore MM, Beith JM.
    Med J Aust; 2008 Mar 17; 188(6):370-1. PubMed ID: 18341464
    [No Abstract] [Full Text] [Related]

  • 29. Yearly zoledronic acid in postmenopausal osteoporosis.
    de Nijs RN, Westgeest AA.
    N Engl J Med; 2007 Aug 16; 357(7):711; author reply 714-5. PubMed ID: 17699824
    [No Abstract] [Full Text] [Related]

  • 30. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep 16; 21(130):204-6. PubMed ID: 23016249
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.
    Oncologist; 2006 Sep 16; 11(7):841-8. PubMed ID: 16880243
    [Abstract] [Full Text] [Related]

  • 32. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.
    Hamdy RC.
    Drug Des Devel Ther; 2010 Nov 18; 4():321-35. PubMed ID: 21151620
    [Abstract] [Full Text] [Related]

  • 33. Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis.
    Taggart H, Cheng J, Archbold P.
    Osteoporos Int; 2010 Sep 18; 21(9):1621-2. PubMed ID: 19813042
    [No Abstract] [Full Text] [Related]

  • 34. First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy.
    Couture G, Delzor F, Bagheri H, Micallef J, Ruyssen-Witrand A, Laroche M.
    Joint Bone Spine; 2017 Mar 18; 84(2):213-215. PubMed ID: 27939801
    [Abstract] [Full Text] [Related]

  • 35. Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis.
    Kulkarni P, Cushman T, Donthireddy V, Rao S.
    BMJ Case Rep; 2016 Feb 03; 2016():. PubMed ID: 26843222
    [Abstract] [Full Text] [Related]

  • 36. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A, Cueva J, Ruiz-Borrego M, Ponce J, Pérez-Fidalgo JA.
    Anticancer Drugs; 2014 Jan 03; 25(1):1-7. PubMed ID: 24100278
    [Abstract] [Full Text] [Related]

  • 37. Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid.
    Perman MJ, Lucky AW, Heubi JE, Azizkhan RG.
    Arch Dermatol; 2009 Jan 03; 145(1):95-6. PubMed ID: 19153360
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
    Lipton A.
    Clin Breast Cancer; 2007 Jul 03; 7 Suppl 1():S14-20. PubMed ID: 17683649
    [Abstract] [Full Text] [Related]

  • 39. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
    Ringe JD, Nitschmann S.
    Internist (Berl); 2008 Apr 03; 49(4):502-4. PubMed ID: 18305914
    [No Abstract] [Full Text] [Related]

  • 40. Zoledronic acid in myeloma: MRC Myeloma IX.
    Rajkumar SV.
    Lancet; 2010 Dec 11; 376(9757):1965-6. PubMed ID: 21131042
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.